Department of Surgery, Obihiro-Kosei General Hospital A 75-year-old woman was referred to our department after she noticed a lump in her left breast and underwent fine-needle aspiration biopsy at a local clinic, which yielded a diagnosis of malignancy. Tumors with a maximum diameter of 30 and 10 mm were palpated in the upper outer quadrant and axillary tail of the left breast, respectively, with skin findings in the upper outer quadrant. A needle biopsy of the tumor in the upper outer quadrant was performed, and a diagnosis of invasive cancer (estrogen receptor (ER) 0%, progesterone receptor (PgR) 0%, HER2-) was made. No findings suggesting distant or axillary lymph node metastases were observed, and neoadjuvant chemotherapy was selected based on the diagnosis of triple-negative breast cancer. Four courses each of docetaxel therapy and FEC100 therapy were given preoperatively. Clinical therapeutic efficacy was partial response (PR) for both the tumor in the upper outer quadrant and the tumor in the axillary tail, and left mastectomy and sentinel lymph node biopsy were performed. Histopathologically, only residual intraductal components were seen in the tumor in the upper outer quadrant, for which the therapeutic efficacy was assessed as Grade 3, while the tumor in the axillary tail was diagnosed as a matrix-producing carcinoma, with a therapeutic efficacy of Grade 0. A csse of matrix-producing carcinoma of the breast, which is histologically relatively rare, treated with neoadjuvant chemotherapy was described. Key words：matrix-producing carcinoma，neoadjuvant chemotherapy
